AbbVie Inc

AbbVie’s first FDA‑approved bispecific antibody, EPKINLY + R2, opens a new front for relapsed follicular lymphoma—offering clinical gains, market edge and $300‑$500 m potential upside.

AbbVie’s musculoskeletal oncology focus, strong cash flow and strategic M&A plans are driving bullish analyst sentiment and higher price targets despite looming patent cliffs.

AbbVie Inc. navigates market volatility and product expansion, with recent FDA approvals poised to influence its revenue trajectory and market positioning, while the company’s diversified portfolio and strategic focus on precision medicine and patie…

AbbVie Inc. has announced a downward revision to its earnings guidance due to a significant investment in research and development and strategic acquisitions, but the company’s diversified revenue streams and promising pipeline of new products, incl…

AbbVie Inc. has revised its earnings guidance downward due to a $2.7 billion research and development charge and market access challenges, but its long-term pipeline and strategic partnerships remain promising for the biotechnology firm.

AbbVie Inc. is experiencing a surge in its share price due to expansion projects, favorable market conditions, and regulatory advancements, but faces looming patent cliffs and increasing competition in key markets.

AbbVie Inc. has announced a series of strategic initiatives to expand its therapeutic portfolio, improve operational efficiency, and navigate market-driven pricing strategies, positioning the company for sustained growth in the biopharmaceutical sec…

AbbVie Inc. has demonstrated resilience in the face of patent expirations and intensifying competition, with a strong market access strategy, pipeline diversification, and shareholder value preservation, positioning the company for sustained growth …

AbbVie Inc. has achieved significant strategic gains through the public reimbursement of its schizophrenia treatment VRAYLAR in Canada, but faces regulatory hurdles, including a recent legal defeat in Mississippi, that may impact its future growth a…

AbbVie’s stock price reached a record high after the company’s drug Rinvoq had its exclusivity extended to 2037, boosting the company’s long-term growth outlook.